Marieke van Son

80 CHAPTER 4 54. Arumainayagam, N.; Kumaar, S.; Ahmed, H.U.; Moore, C.M.; Payne, H.; Freeman, A.; Allen, C.; Kirkham, A.; Emberton, M. Accuracy of multiparametric magnetic resonance imaging in detecting recur- rent prostate cancer after radiotherapy. BJU international 2010, 106, 991-997; DOI: 10.1111/j.1464-410X.2010.09291.x. 55. Gaur, S.; Turkbey, B. Prostate mr imaging for posttreatment evaluation and recur- rence. Radiologic clinics of North Amer- ica 2018, 56, 263-275; DOI: 10.1016/j. rcl.2017.10.008. 56. Oppenheimer, D.C.; Weinberg, E.P.; Hol- lenberg, G.M.; Meyers, S.P. Multipara- metric magnetic resonance imaging of recurrent prostate cancer. Journal of clinical imaging science 2016, 6, 18; DOI: 10.4103/2156-7514.181494. 57. Panebianco, V.; Barchetti, F.; Grompone, M.D.; Colarieti, A.; Salvo, V.; Cardone, G.; Catalano, C. Magnetic resonance imag- ing for localization of prostate cancer in the setting of biochemical recurrence. Urol Oncol 2016, 34, 303-310; DOI: 10.1016/j.urolonc.2016.01.004. 58. Patel, P.; Mathew, M.S.; Trilisky, I.; Oto, A. Multiparametric mr imaging of the pros- tate after treatment of prostate cancer. Radiographics : a review publication of the Radiological Society of North Amer- ica, Inc 2018, 38, 437-449; DOI: 10.1148/ rg.2018170147. 59. Hotker, A.M.; Meier, A.; Mazaheri, Y.; Zheng, J.; Capanu, M.; Chaim, J.; Sosa, R.; Coleman, J.; Hricak, H.; Akin, O. Tem- poral changes in mri appearance of the prostate after focal ablation. Abdominal radiology 2018; DOI: 10.1007/s00261- 018-1715-9. 60. Taneja, S.; Jena, A.; Taneja, R.; Singh, A.; Ahuja, A. Effect of combined (68) ga-psmahbed-cc uptake pattern and multiparametric mri derived with simul- taneous pet/mri in the diagnosis of pri- mary prostate cancer: Initial experience. AJR. American journal of roentgenolo- gy 2018, 210, 1338-1345; DOI: 10.2214/ AJR.17.18881. 61. Afshar-Oromieh, A.; Avtzi, E.; Giesel, F.L.; Holland-Letz, T.; Linhart, H.G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B.A.; Kratochwil, C., et al. The diagnos- tic value of pet/ct imaging with the (68) ga-labelled psma ligand hbed-cc in the diagnosis of recurrent prostate cancer. European journal of nuclear medicine and molecular imaging 2015, 42, 197- 209; DOI: 10.1007/s00259-014-2949-6. 62. Han, S.; Woo, S.; Kim, Y.J.; Suh, C.H. Impact of (68)ga-psma pet on the management of patients with prostate cancer: A systematic review and me- ta-analysis. Eur Urol 2018, 74, 179-190; DOI: 10.1016/j.eururo.2018.03.030. 63. Kasivisvanathan, V.; Rannikko, A.S.; Borghi, M.; Panebianco, V.; Myn- derse, L.A.; Vaarala, M.H.; Briganti, A.; Budaus, L.; Hellawell, G.; Hindley, R.G., et al. Mri-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018, 378, 1767-1777; DOI: 10.1056/ NEJMoa1801993. 64. Tran, M.; Thompson, J.; Bohm, M.; Pul- brook, M.; Moses, D.; Shnier, R.; Brenner, P.; Delprado, W.; Haynes, A.M.; Savdie, R., et al. Combination of multiparametric mri and transperineal template-guided mapping biopsy of the prostate to iden- tify candidates for hemi-ablative focal therapy. BJU international 2016, 117, 48-54; DOI: 10.1111/bju.13090. 65. Wegelin, O.; Exterkate, L.; Somford, D.; Barentsz, J.; Van Der Leest, M.; Kummer, A.; Vreuls, W.; De Bruin, P.; Bosch, R.; Van Melick, H. The future trial; amulticenter rct on three techniques of mri targeted pros- tate biopsy. In EAU 18, Copenhagen, 2018. 66. Crook, J.; Malone, S.; Perry, G.; Bahadur, Y.; Robertson, S.; Abdolell, M. Postradiother- apy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000, 48, 355-367.